Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:390643.
doi: 10.1155/2010/390643. Epub 2010 Aug 31.

Mesoglycan: clinical evidences for use in vascular diseases

Antonella Tufano  1 , Claudia Arturo, Ernesto Cimino, Matteo Nicola Dario Di Minno, Mirko Di Capua, Anna Maria Cerbone, Giovanni Di Minno
Affiliations

Mesoglycan: clinical evidences for use in vascular diseases

Antonella Tufano et al. Int J Vasc Med. 2010.

Abstract

Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be involved in several biologic functions. Mesoglycan, a natural GAG preparation, is a polysaccharide complex rich in sulphur radicals with strong negative electric charge. It is extracted from porcine intestinal mucosa and is composed of heparan sulfate, dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate. Data on antithrombotic and profibrinolytic activities of the drug show that mesoglycan, although not indicated in the treatment of acute arterial or venous thrombosis because of the low antithrombotic effect, may be useful in the management of vascular diseases, when combined with antithrombotics in the case of disease of cerebral vasculature, and with antithrombotics and vasodilator drugs in the case of chronic peripheral arterial disease. The protective effect of mesoglycan in patients with venous thrombosis and the absence of side effects, support the use of GAG in patients with chronic venous insufficiency and persistent venous ulcers, in association with compression therapy (zinc bandages, multiple layer bandages, etc.), elastic compression stockings, and local care, and in the prevention of recurrences in patients with previous DVT following the standard course of oral anticoagulation treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vittoria A, Messa GL, Frigerio C, Celasco G, Auteri A. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses. International Journal of Tissue Reactions. 1988;10(4):261–266. - PubMed
    1. Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis. 1987;17(6):329–335. - PubMed
    1. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparin sulfate and dermatan sulfate. Thrombosis Research. 1976;8(6):859–867. - PubMed
    1. Abbadini M, Zhu GJ, Maggi A, Pangrazzi J, Donati MB, Mussoni L. Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. Blood. 1987;70(6):1858–1860. - PubMed
    1. Restori G, Boiardi L, Mari S, et al. Glycosaminoglycans administration (heparan sulphate, dermatan-sulphate and their combinations 50:50) and reduction of atherosclerosis progression rate in rabbits with a diet-induced hypercholesterolemia. Atherosclerosis and Cardiovascular Disease. 1989;4:971–975.

LinkOut - more resources